Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Apoptosis
    (8)
  • Autophagy
    (12)
  • MEK
    (6)
  • PDGFR
    (10)
  • Raf
    (70)
  • Src
    (7)
  • VEGFR
    (12)
  • c-Kit
    (9)
  • c-RET
    (7)
  • Others
    (51)
Filter
Search Result
Results for "Raf" in TargetMol Product Catalog
  • Inhibitor Products
    135
    TargetMol | Activity
  • Natural Products
    7
    TargetMol | inventory
  • Recombinant Protein
    4
    TargetMol | natural
  • Compound Libraries
    3
    TargetMol | composition
  • Peptides Products
    3
    TargetMol | Activity
  • PROTAC Products
    3
    TargetMol | inventory
  • Isotope products
    2
    TargetMol | natural
B-Raf IN 16
T798302304746-24-3In house
B-Raf IN 16, a BRAF inhibitor, belongs to cyclic iminopyrimidine derivatives and can be used for cancer or tumour research.
  • $195 TargetMol
In Stock
Size
QTY
TargetMol | Inhibitor Sale
B-Raf IN 14
T72070326918-98-3
B-Raf IN 14 is a BRAF inhibitor.
  • $195
In Stock
Size
QTY
TargetMol | Inhibitor Sale
B-Raf IN 15
T78183832107-31-0In house
B-Raf IN 15 is a BRAF inhibitor that inhibits BRAFWT and BRAFV600E and can be used in the study of melanoma and cancer, and can be optimized for use as a more effective BRA F inhibitor.
  • $52
In Stock
Size
QTY
TargetMol | Inhibitor Sale
B-Raf IN 13
T678622573782-74-6In house
B-Raf IN 13 is a potent B-Raf inhibitor with anticancer activity.B-Raf IN 13 has an IC50 of 3.55 nM in the BRAF V600E enzyme assay.
  • $1,520
6-8 weeks
Size
QTY
RAF709
T37111628838-42-5
RAF709 is a novel Raf kinase inhibitor with IC50s of 0.5 and 1.8 nM for c-Raf and b-Raf, respectively.
  • $34
In Stock
Size
QTY
TargetMol | Citations Cited
B-Raf IN 2
T402842649372-20-1
B-Raf IN 2, compound Ia, is a highly effective and specific inhibitor of BRAF. It exhibits significant potential for cancer research.
  • $52
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Raf inhibitor 2
T4194220904-99-4
Raf inhibitor 2 (CID 25014542) is novel inhibitor of Raf kinases.
  • $39
In Stock
Size
QTY
TargetMol | Inhibitor Sale
B-Raf IN 11
T19802918504-27-5
B-Raf IN 11 is a novel selective inhibitor. The DFG-in conformation of the B-Raf kinase V600E mutant is superior to the DFG-out conformation in colorectal cancer.
  • $30
In Stock
Size
QTY
TargetMol | Inhibitor Sale
PROTAC B-Raf degrader 1
T125562364367-27-9
PROTAC B-Raf degrader 1 is a proteolysis targeting chimera (PROTAC) for the degradation of B-Raf,PROTAC B-Raf degrader 1 With anti-cancer activity.
  • $431
Backorder
Size
QTY
C-RAF kinase-IN-1
T72605
C-RAF kinase-IN-1 is a potent inhibitor of C-RAF kinase with an IC 50 of 0.193 μM. C-RAF kinase-IN-1 is a quinoline derivative. C-RAF kinase-IN-1 has the potential for the research of cancer diseases .
  • $1,520
6-8 weeks
Size
QTY
Raf inhibitor 1 dihydrochloride
T41671191385-19-9
Raf inhibitor 1 dihydrochloride (B-Raf inhibitor 1 dihydrochloride) is a potent and selective B-Raf inhibitor.
  • $42
In Stock
Size
QTY
Uplarafenib
T633331425485-87-5
Uplarafenib (B-Raf IN 10) is a potent BRAF inhibitor with an IC50 in the range of 50-100 nM.B-Raf IN 10 has antitumor activity that may affect cell proliferation and differentiation did not, and can be used to study solid tumors.
  • $87
In Stock
Size
QTY
B-Raf IN 8
T607271215313-19-1
B-Raf IN 8 (compound 7g) is a potent inhibitor of B-Raf (IC 50 = 70.65 nM). B-Raf IN 8 shows antitumor activity which has IC 50 values of 9.78, 13.78, 18.52 and 29.85 μM against hepatocellular carcinoma (HEPG-2), colon carcinoma (HCT-116), mammary gland (MCF-7) and human prostate cancer (PC-3) cells [1].
  • $1,520
6-8 weeks
Size
QTY
Raf inhibitor 1
T20741093100-40-3
B-Raf inhibitor 1 (B-Raf inhibitor 1) is a potent and selective B-Raf inhibitor.
  • $32
In Stock
Size
QTY
B-Raf IN 6
T638552648698-34-2
B-Raf IN 6 is a potent inhibitor (IC50: 1.7 nM) of the protein kinase B-Raf, which does not bind the secondary target PXR and is resistant to rapid metabolism.B-Raf IN 6 has shown research potential in cancer diseases.
  • $1,520
6-8 weeks
Size
QTY
B-Raf IN 1
T1845950736-05-7
B-Raf IN 1 is a B-Raf (IC50: 24 nM) and c-Raf (IC50: 25 nM) inhibitor.
  • $84
In Stock
Size
QTY
Exarafenib
T636442639957-39-2
Exarafenib (RAF/KIN_2787) is a potent and orally available pan-RAF inhibitor.Exarafenib has antitumor activity and acts by inhibiting downstream MAPK pathway signaling.Exarafenib is used in cancer research.
  • $131
In Stock
Size
QTY
Raf inhibitor 3
T798131662682-11-2
Raf inhibitor 3 (Example 30), a potent inhibitor of both B-Raf and C-Raf, exhibits IC50 values below 15 nM. It is applicable in cancer research studies [1].
  • Inquiry Price
Size
QTY
B-Raf IN 9
T619352477725-18-9
B-Raf IN 9 (compound 8b) is an effective B-Raf inhibitor (IC50=24.79 nM). B-Raf IN 9 blocks cell cycle at G2/M phase and induces apoptosis. B-Raf IN 9 showed potent anti-tumor activity on human prostate cancer PC-3 cells (IC50=7.83 μM).
  • $1,520
6-8 weeks
Size
QTY
RAF mutant-IN-1
T126852340020-82-6
RAF mutant-IN-1 is an inhibitor of RAF kinase(IC50 values of 21 nM, 30 nM and 392 nM for C-RAF 340D/Y341D, B-RAFV600E and B-RAFWT, respectively).
  • $2,120
8-10 weeks
Size
QTY
RAS/RAS-RAF-IN-1
T366422447039-81-6
RAS/RAS-RAF-IN-1 is a potent RAS and RAS-RAF inhibitor. RAS/RAS-RAF-IN-1 has a KD of 5.0 μμ-15 μμ for cyclophilin A (CYPA) binding affinity. RAS/RAS-RAF-IN-1 has antitumor activity[1]. RAS/RAS-RAF-IN-1 (compound 89; for 4 hours) has an EC50 of 0.5 μμ-5.0 μμ for BRAF-GTP-KRAS-G12C disruption and has an IC50 of 1.0 μμ-10 μμ for pERK inhibition in H358 cells[1]. [1]. Meizhong Jin, et al. Compounds that participate in cooperative binding and uses thereof. WO2020132597A1.
  • $1,160
Backorder
Size
QTY
Pan-RAF kinase inhibitor 1
T633862648838-76-8
Pan-RAF kinase inhibitor 1 is a potent inhibitor of the Pan-RAF kinase pair that inhibits RAF kinase and regulates MAPK signaling, thereby affecting the proliferation of RAS-mutated tumor cells. Pan-RAF kinase inhibitor 1 has shown research potential for the study of cancer diseases.
  • $2,140
8-10 weeks
Size
QTY
RAF265
T6296927880-90-8
RAF265 (CHIR-265) (CHIR-265) is a potent selective inhibitor of C-Raf/B-Raf/B-Raf V600E with IC50 of 3-60 nM, and exhibits potent inhibition on VEGFR2 phosphorylation with EC50 of 30 nM. Phase 2.
  • $39
In Stock
Size
QTY
B-Raf IN 7
T609332477725-07-6
B-Raf IN 7 (compound 6a) is a potent inhibitor of B-Raf with an IC 50 of 110.23 nM. B-Raf IN 7 has antitumor activity against colon carcinoma cells(HCT-116), mammary gland cells(MCF-7), hepatocellular carcinoma cells(HEPG-2), human cervical carcinoma cells(Hela) and human prostate cancer cells(PC-3). The IC50 values are 7.50, 9.87, 10.57, 11.63 and 12.83 μM, respectively [1].
  • $1,520
6-8 weeks
Size
QTY
RAF-IN-1
T633652695505-82-7
RAF-IN-1 is a potent inhibitor of b/cRAF, acting on cRAF (IC50: 3.8 nM), bRAFwt (IC50: 36 nM), bRAFV600E (IC50: 29.4 nM) and inhibiting A375 and H358 cell lines carrying the bRAFV600E mutation with a GI50 of 3.4 and 2.9 nM.
  • $1,520
6-8 weeks
Size
QTY
B-Raf IN 5
T641162648698-30-8
B-Raf IN 5 is a potent inhibitor of the protein kinase B-Raf (IC50: 2.0 nM). B-Raf IN 5 resists rapid metabolism and does not bind to the secondary target PXR.
  • $1,520
8-10 weeks
Size
QTY
Regorafenib
T1792755037-03-7
Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor that inhibits RET, C-RAF, VEGFR2, c-Kit, VEGFR1, and PDGFRβ and is orally active. Regorafenib has antitumor and anti-angiogenic activity.
  • $30
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
AWL-II-38.3
T385111135205-94-5
AWL-II-38.3 is a highly effective inhibitor of EphA3, a receptor for ephrin-A. It demonstrates potent kinase inhibitory activity against EphA3 and does not show significant cellular activity against Src-family kinases or b-raf [1] [2].
  • $74
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Sorafenib
T0093L284461-73-0
Sorafenib (Bay 43-9006) is a multikinase inhibitor that inhibits Raf-1, B-Raf, VEGFR2, VEGFR3, VEGFR4, PDGFRβ, FLT3, c-Kit, and others (IC50=6/22/90/15/20/20/57/58 nM) with oral activity. Sorafenib has antitumor activity and can induce autophagy and apoptosis as well as agonistic iron death.
  • $34
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
Belvarafenib
T56341446113-23-0
Belvarafenib is a potent and pan RAF inhibitor with antineoplastic activity. The IC50 values of Belvarafenib are 56 nM, 7 nM and 5 nM for B-RAF, B-RAFv600E and C-RAF respectively.
  • $40
In Stock
Size
QTY
TargetMol | Inhibitor Hot
PLX-4720
T2473918505-84-7
PLX-4720 is a potent and selective inhibitor of B-Raf (V600E) (IC50: 13 nM), equally potent to c-Raf-1(Y340D and Y341D mutations).
  • $32
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Dabrafenib
T19031195765-45-7
Dabrafenib (GSK2118436A) is a Raf inhibitor that inhibits C-Raf and B-RafV600E (IC50=5/0.6 nM) and is ATP-competitive. Dabrafenib exhibits antitumor activity for the treatment of B-RafV600E-mutated melanoma.
  • $41
In Stock
Size
QTY
TargetMol | Inhibitor Hot
LXH254
T118981800398-38-2
LXH254 is a potent C-Raf and B-Raf inhibitor.
  • $48
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Sulindac sulfide
T1303749627-27-2In house
Sulindac sulfide (cis-Sulindac sulfide) is a non-steroidal anti-inflammatory compound that has a high affinity for COX-1 and acts as an inhibitor in Ras activation of Raf-1. Sulindac sulfide is a non-competitive inhibitor of gamma-secretase with an IC50 value of 20.2 μM. It is an active metabolite of sulinic acid.
  • $31
In Stock
Size
QTY
GSK2008607
T274541244644-50-5In house
GSK2008607 is a potent B-RafV600E inhibitor with anticancer activity and can be used to study breast, colorectal, melanoma, thyroid, and ovarian cancers.
  • $350
In Stock
Size
QTY
Plx-4032
T86541029872-54-5
Plx-4032 (Vemurafenib) is a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma.
  • $50
In Stock
Size
QTY
CCT241161
T96381163719-91-2In house
CCT241161 is an orally active pan-RAF inhibitor, with IC50 values of 3, 6, 10, 15, and 30 nM for LCK, CRAF, SRC, V600E-BRAF, and BRAF, respectively. It displays significant activity against BRAF and NRAS mutant melanomas, as well as demonstrating anticancer cell proliferative effects [1].
  • $139
In Stock
Size
QTY
TargetMol | Inhibitor Sale
AMG PERK 44
T102991883548-84-2In house
AMG PERK 44 is an orally active and selective PERK inhibitor (IC50: 6 nM) that induces autophagy.AMG PERK 44 inhibits GCN2 (IC50: 7300 nM) and B-Raf (IC50 >1000 nM) and can be used in the study of cancer.
  • Inquiry Price
6-8 weeks
Size
QTY
TargetMol | Inhibitor Sale
BRAF inhibitor
T10599918505-61-0In house
BRAF inhibitor is an inhibitor of B-Raf.
  • $39
In Stock
Size
QTY
INU-152
T276141380228-30-7In house
INU-152 is a pan-RAF inhibitor. INU-152 has potent anti-tumor activity in preclinical models of BRAFV600E mutant cancer. INU-152 inhibits all RAF isoforms and inhibits MAPK pathways in mutant BRAF cells. INU-152 exhibits minimal paradoxical pathway activa
  • $1,820
8-10 weeks
Size
QTY
TargetMol | Inhibitor Sale
AD80
T43011384071-99-1
AD80, a multikinase inhibitor, inhibits RET, RAF, SRCand S6K, with greatly reduced mTOR activity.
  • $39
In Stock
Size
QTY
TargetMol | Citations Cited
Doramapimod
T6277285983-48-4
Doramapimod (BIRB 796) is a highly potent inhibitor of p38 MAPK (Kd: 0.1 nM), but weakly inhibits c-RAF, Fyn, Lck, ERK-1, SYK, IKK2, and ZAP-70.
  • $31
In Stock
Size
QTY
TargetMol | Citations Cited
TAK-632
T18861228591-30-7
TAK-632 is a potent pan-Raf inhibitor.
  • $35
In Stock
Size
QTY
TargetMol | Citations Cited
SB-590885
T2295405554-55-4
SB590885 is an effective B-Raf inhibitor (Ki: 0.16 nM, in a cell-free assay). The selectivity of SB590885 for B-Raf is 11-fold greater over c-Raf, no acts to other human kinases.
  • $36
In Stock
Size
QTY
TargetMol | Citations Cited
Cyclorasin 9A5
T826371782098-79-6
Cyclorasin 9A5 is a cell-permeable, 11-residue cyclic peptide that orthosterically disrupts the Ras-Raf protein interaction, demonstrating an inhibition concentration (IC50) of 120 nM [1].
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
LUT014
T157942274819-46-2
LUT014 is a B-Raf inhibitor (IC50: 11.7 nM) and developed to decrease dose-limiting acneiform lesions associated with EGFR Inhibitors treatment.
  • $84
In Stock
Size
QTY
TargetMol | Inhibitor Sale
AZ304
T5172942507-42-8
AZ304 is an ATP-competitive dual BRAF kinase inhibitor, potently inhibits BRAF (WT), BRAF (V600E), and wild type CRAF (IC50s: 79/38/68 nM).
  • $42
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Pseudoginsenoside Rh2
TN21141370264-16-6
Pseudoginsenoside Rh2 has cytotoxicity, it induces mitochondrial apoptosis in A549 cells and is responsible for excessive activation of the Ras/Raf/ERK/p53 pathway. (20Z) -Pseudoginsenoside Rh2 and (20E)-Pseudoginsenoside Rh2 have antioxidative activity.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
KG5
T41003877874-85-6
KG5 is a dual allosteric inhibitor of PDGFRβ and B-Raf with a Kd of 520 nM and 300 nM for PDGFRβ and PDGFRα. KG5 inhibits FLT3, KIT, and c-Raf with anticancer and antiangiogenic activities.
  • $48
In Stock
Size
QTY
TargetMol | Inhibitor Sale
R18
TP2127211364-78-2
Antagonist of 14.3.3 proteins (KD ≈80 nM). Competitively inhibits 14.3.3-ligand interactions without requiring phosphorylation. Blocks the ability of 14.3.3 to bind to target proteins such as Raf-1, Bad, ASK1 and exoenzyme S.
  • $1,130
35 days
Size
QTY
TargetMol | Inhibitor Sale